Latest News about JNJ
Recent news which mentions JNJ
   Sit Out Market Drama With These 3 Dividend Funds
   
  
  
  April 04, 2025
  From Benzinga
 From Benzinga
 From Benzinga
 
   Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts
   
  
  
  April 03, 2025
  From Benzinga
 From Motley Fool
 
   What 13 Analyst Ratings Have To Say About Johnson & Johnson
   
  April 02, 2025
  Tickers 
   JNJ
  
  
  From Benzinga
 From Benzinga
 
   Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today
   
  
  
  April 01, 2025
  From Benzinga
 
   Johnson & Johnson Stock Is Tumbling Tuesday: What Going On?
   
  
  
  April 01, 2025
  From Benzinga
 From Benzinga
 From Benzinga
 
   US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims
   
  
  
  April 01, 2025
  From Benzinga
 
   2 Value Stocks I'm Buying Right Now
   
  
  
  April 01, 2025
  From Motley Fool
 
   Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend
   
  
  
  March 31, 2025
  From Benzinga
 
   Is Hims & Hers Stock Too Cheap to Pass Up?
   
  
  
  March 29, 2025
  From Motley Fool
 
   3 Relatively Safe Stocks to Buy Right Now
   
  
  
  March 29, 2025
  From Motley Fool
 From Motley Fool
 
   2 Recession-Proof Dividend Stocks to Buy and Hold
   
  
  
  March 27, 2025
  From Motley Fool
 From Benzinga
 From Benzinga
 
   FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
   
  
  
  March 21, 2025
  From Benzinga
 From Benzinga
 
   Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
   
  March 20, 2025
  Tickers 
   JNJ
  
  
  From Benzinga
 From Motley Fool
 
   Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
   
  
  
  March 18, 2025
  From Benzinga
 
   FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
   
  
  
  March 18, 2025
  From Benzinga
 
   Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
   
  
  
  March 18, 2025
  From Benzinga
 From Motley Fool
 From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.